Comparison · NCT00087178-sae
Adriamycin + Cyclophosphamide vs Fluorouracil + Epirubicin + Cyclophosphamide: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Adriamycin + Cyclophosphamide vs Fluorouracil + Epirubicin + Cyclophosphamide: serious adverse events. Trial comparisons, record NCT00087178-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00087178-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00888 | 0.00509 | 0.0155 | wilson | |
| Risk in group 2 | 0.0194 | 0.0133 | 0.0283 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0106 | -0.0202 | -0.00156 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.457 | 0.231 | 0.901 | log | |
| Odds ratio, group 1 over group 2 | 0.452 | 0.227 | 0.899 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Adriamycin + Cyclophosphamide than on Fluorouracil + Epirubicin + Cyclophosphamide | 94.7 | 49.4 | 639 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Adriamycin + Cyclophosphamide | Patients receive adriamycin IV over 15 minutes followed by cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses.~cyclophosphamide: Arm 1: cyclophosphamide 600 mg/m2 IV every 21 days for 4 cycles; Arm 2: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~adriamycin: adriamycin 60 mg/m2 IV every 21 days for 4 cycles | 12 | 1,351 | EG000 |
| Group 2 | Fluorouracil + Epirubicin + Cyclophosphamide | Patients receive fluorouracil IV, epirubicin IV over 15 minutes, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses.~cyclophosphamide: Arm 1: cyclophosphamide 600 mg/m2 IV every 21 days for 4 cycles; Arm 2: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~epirubicin: epirubicin 100 mg/m2 IV every 21 days for 6 cycles~fluorouracil: fluorouracil 500 mg/m2 IV every 21 days for 6 cycles | 26 | 1,337 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
- NCT number
- NCT00087178
- Phases
- PHASE3
- Conditions
- Breast Cancer
- Interventions
- cyclophosphamide, adriamycin, epirubicin, fluorouracil
- Lead sponsor
- NSABP Foundation Inc
- Results first posted
- 2022-08-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00087178?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00087178-sae